Mavefund EN
Candel Therapeutics Inc logo

Candel Therapeutics Inc

CADL
Letzter Kurs (USD) US$12.86
Marktkapitalisierung (USD) US$928.9m
Kursänderung 12 Monate 122.11%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Halozyme Therapeutics IncHALO Vergleich Corcept Therapeutics IncorporatedCORT Vergleich Exelixis IncEXEL Vergleich Zoetis IncZTS Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Candel Therapeutics Inc Überblick

Branche: Biotechnology

Sektor: Healthcare

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer

Research-Überblick

Letztes Berichtsdatum 2026-08-13

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Candel Therapeutics Inc (CADL): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
CADL · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Biotechnology
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-13
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Candel Therapeutics Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 13, 2026

Quarterly result summary

Net loss was -$38.9M (from $4.8M). R&D expense was $19.8M.

Net loss -$38.9M from $4.8M
R&D expense $19.8M reported
G&A expense $6.9M reported
Cash $201.6M reported

Was sich verändert hat

  • Net loss was -$38.9M (from $4.8M).

Guidance / outlook

the Company expects that its existing cash and cash equivalents, as of June 30, 2026, will be sufficient to fund operations into Q1 2028. About aglatimagene besadenovec Aglatimagene, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumo...

Earnings material Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing 10-Q Aug 13, 2026 SEC filing 8-K Aug 13, 2026 SEC filing 10-Q May 14, 2026 SEC filing 8-K May 14, 2026 Earnings release Earnings release May 14, 2026 SEC filing 10-K Mar 12, 2026 SEC filing 8-K Mar 12, 2026 Earnings release Earnings release Mar 12, 2026 SEC filing 8-K Feb 19, 2026 SEC filing 10-Q Nov 13, 2025 SEC filing 8-K Nov 13, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 1.00/5
Candel Therapeutics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Eigenkapitalrendite

Score 0.38/5
Candel Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Candel Thera... CADL US$928.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 0.15/5
Candel Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Candel Thera... CADL US$928.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Verschuldung

Score 2.47/5
Candel Therapeutics Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
Candel Thera... CADL US$928.9m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Candel Therapeutics Inc logo

Candel Therapeutics Inc

US$12.86

US$928.9m

0.08%

122.11%